S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:GPCR

Structure Therapeutics (GPCR) Stock Price, News & Analysis

$42.86
-0.05 (-0.12%)
(As of 03/28/2024 ET)
Today's Range
$41.91
$44.37
50-Day Range
$33.90
$49.00
52-Week Range
$21.58
$75.02
Volume
380,258 shs
Average Volume
894,385 shs
Market Capitalization
$2.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$89.17

Structure Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
108.0% Upside
$89.17 Price Target
Short Interest
Bearish
8.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.21mentions of Structure Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.96) to ($0.76) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.78 out of 5 stars

Medical Sector

687th out of 938 stocks

Pharmaceutical Preparations Industry

307th out of 417 stocks

GPCR stock logo

About Structure Therapeutics Stock (NASDAQ:GPCR)

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

GPCR Stock Price History

GPCR Stock News Headlines

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
GPCR Dec 2024 50.000 call
GPCR Sep 2024 30.000 put
GPCR May 2024 30.000 put
GPCR Apr 2024 30.000 put
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
GPCR Mar 2024 40.000 put
GPCR Mar 2024 60.000 call
Baron Opportunity Fund Q4 2023 Shareholder Letter
Here’s Why Structure Therapeutics (GPCR) Fell in Q4
GPCR Structure Therapeutics Inc.
See More Headlines
Receive GPCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Structure Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/29/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GPCR
Fax
N/A
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$89.17
High Stock Price Target
$97.00
Low Stock Price Target
$79.00
Potential Upside/Downside
+108.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-89,620,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$9.77 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.00 billion
Optionable
Optionable
Beta
N/A
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Raymond C. Stevens Ph.D. (Age 60)
    CEO & Director
    Comp: $747.33k
  • Dr. Yingli Ma Ph.D. (Age 50)
    Chief Technology Officer
    Comp: $497.58k
  • Dr. Mark A. Bach M.D. (Age 67)
    Ph.D., Chief Medical Officer
    Comp: $628.37k
  • Mr. Jun S. Yoon (Age 46)
    Co- Founder, CFO & Secretary
  • Dr. Xichen Lin Ph.D. (Age 50)
    Chief Scientific Officer
  • Mr. Tony Peng
    Senior Vice President of Legal
  • Mr. Bob Gatmaitan
    Senior Vice President of People
  • Dr. Hui Lei Ph.D.
    Senior Vice President of Chemistry
  • Dr. Fang Zhang Ph.D.
    Executive VP & Head of Biology
  • Ms. Lani Ibarra
    Senior Vice President of Clinical Development Operations

GPCR Stock Analysis - Frequently Asked Questions

Should I buy or sell Structure Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Structure Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GPCR shares.
View GPCR analyst ratings
or view top-rated stocks.

What is Structure Therapeutics' stock price target for 2024?

5 analysts have issued 12 month price targets for Structure Therapeutics' stock. Their GPCR share price targets range from $79.00 to $97.00. On average, they expect the company's share price to reach $89.17 in the next twelve months. This suggests a possible upside of 108.0% from the stock's current price.
View analysts price targets for GPCR
or view top-rated stocks among Wall Street analysts.

How have GPCR shares performed in 2024?

Structure Therapeutics' stock was trading at $40.76 at the beginning of 2024. Since then, GPCR stock has increased by 5.2% and is now trading at $42.86.
View the best growth stocks for 2024 here
.

When is Structure Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our GPCR earnings forecast
.

What ETFs hold Structure Therapeutics' stock?

ETFs with the largest weight of Structure Therapeutics (NASDAQ:GPCR) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Fidelity Disruptive Medicine ETF (FMED).

When did Structure Therapeutics IPO?

Structure Therapeutics (GPCR) raised $150 million in an IPO on Friday, February 3rd 2023. The company issued 10,740,000 shares at a price of $13.00-$15.00 per share.

Who are Structure Therapeutics' major shareholders?

Structure Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Wellington Management Group LLP (9.43%), Avoro Capital Advisors LLC (5.03%), Federated Hermes Inc. (4.89%), Price T Rowe Associates Inc. MD (3.62%), Price T Rowe Associates Inc. MD (3.62%) and Capital Research Global Investors (2.10%).

How do I buy shares of Structure Therapeutics?

Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GPCR) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners